Clinical trials: Type Two Diabetes Mellitus
Diabetes Mellitus, Type 2
Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus
The purpose of this study is to show the non-inferiority of insulin glulisine administered with 1 meal versus 2 meals versus 3 daily meals, as measured by the change in hemoglobin A1c (HbA1c), from baseline to study week 24.
- Trial name
- NCT00135083
- Testing
- insulin glulisine
- Volunteers
- 347 people
- Sponsor
- Sanofi
T2DM (Type 2 Diabetes Mellitus)
Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393
A Clinical Trial to evaluate the Pharmacokinetics and safety of CKD-393 0.5/100/1000 mg under fed condition
- Trial name
- NCT04706286
- Testing
- CKD-501, D759, D150, CKD-393 0.5/100/1000 mg
- Where
- South Korea
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus
To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately
This is an open-label, randomised study to compare the similarity of a combination Dapagliflozin/Metformin tablet with the two drugs administered separately under fasting and fed conditions in healthy volunteers.
- Trial name
- NCT01535677
- Testing
- Dapagliflozin + Glucophage tablet fasted, Dapagliflozin/metformin IR FDC tablet fasted, Dapagliflozin + Glucophage tablet fed
- Where
- United Kingdom
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate pharmacokinetics, pharmacodynamics and safety of biphasic insulin aspart 30 in subjects with type 2 diabetes.
- Trial name
- NCT01697618
- Testing
- biphasic insulin aspart 30, biphasic human insulin 30
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029
Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D745, D150 and D029 for Healthy Subjects in Fed State
- Trial name
- NCT05897216
- Testing
- CKD-383, CKD-501, D745, D150, D029
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetes Mellitus, Type 2
A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before
This study compares insulin 287 (a possible new medicine) to insulin glargine (a medicine doctors can already prescribe) in people with type 2 diabetes. Different ways of changing the dose of insulin 287 are also compared.
- Trial name
- NCT03951805
- Testing
- Insulin icodec, Insulin Glargine
- Where
- 43 sites in United States, Croatia and 5 more
- Volunteers
- 205 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)
The purpose of this study is to determine if LY2189265 is effective in reducing hemoglobin A1c (HbA1c) and safe, as compared to Insulin Glargine in participants with Type 2 Diabetes.
- Trial name
- AWARD-2 (NCT01075282)
- Testing
- Insulin Glargine, LY2189265, Metformin
- Where
- 78 sites in Argentina, Australia and 18 more
- Volunteers
- 810 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes
The purpose of the study is to find out if the new tablet formulation oral semaglutide D is equally safe and effective as the approved oral semaglutide for treating Japanese people with type 2 diabetes.
- Trial name
- NCT07271251
- Testing
- Oral semaglutide
- Where
- 15 sites in Japan
- Volunteers
- 267 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
A Phase 2 Two-Part Study of Oral PS1 in Healthy Volunteers and Adults With Newly Diagnosed Type 1 Diabetes
This study consists of 2 sub-studies, including Part A and Part B. Part A is intended to further characterize the pharmacokinetic (PK) profile of PS1 based on existing single ascending dose (SAD) and multiple ascending dose (MAD)…
- Trial name
- NCT07889505
- Testing
- PS1
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pharmasaga Co. Ltd.
Type 2 Diabetes Mellitus (T2DM)
Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets
Randomized, Single Oral Dose, Two-period, Two Sequence, Open-label, Crossover, Bioequivalence Study to Compare Empagliflozin-Linagliptin-Metformin XR Tablet 25mg/ 5mg/1000mg (25mg Empagliflozin /5mg Linagliptin /1000mgMetformin…
- Trial name
- NCT07213895
- Testing
- Empagliflozin/Linagliptin/Metformin HCL, Trijardy® XR Extended release film coated tablets
- Where
- Jordan
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Diabetes
Glycemic Response to Two Enteral Formulas in Persons With Type 2 Diabetes Mellitus
This will be a randomized, cross-over design. Subjects will be randomized to one of two interventions on two separate study days, 1 week apart.
- Trial name
- NCT02898766
- Testing
- Enteral Nutrition Formula
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Société des Produits Nestlé (SPN)
Diabetes, Diabetes Mellitus, Type 2
Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes
This trial is conducted in Africa and Middle East. The objective of the study is to compare glycemic control of Biphasic insulin Aspart 30 twice daily with Biphasic insulin Aspart 30 twice daily plus Insulin Aspart, both insulin…
- Trial name
- NCT00282451
- Testing
- biphasic insulin aspart, insulin aspart
- Where
- 4 sites in Egypt, Saudi Arabia
- Volunteers
- 79 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study
This is a phase 1, single dose, randomised, double-blind, two-way crossover study to compare ultra-rapid-acting concentrated insulin aspart AT278 (U500/mL) with standard insulin aspart NovoRapid® (U100/mL) in participants with…
- Trial name
- NCT05754424
- Testing
- AT278, NovoRapid, Humulin R 500 UNT/ML Injectable Solution
- Where
- Austria
- Volunteers
- 41 people
- Sponsor
- Arecor Limited
Hypertension, Diabete Type 2
Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of HL1113-R1 and HL1113-R2 in Healthy Adult Volunteers
This clinical trial is a two-arm, open-label, single-sequence, multiple oral dosings, cross-over design clinical trial to evaluate the safety and pharmacokinetic characteristics of HL1113-R1 and HL1113-R2 in healthy adult…
- Trial name
- NCT07598968
- Testing
- Test group 1, Test group 2
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Healthy Volunteers, Overweight
First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes
The purpose of this study is to investigate how safe, and how well tolerated, the new study drug NNC0480-0389 is when it is given together with semaglutide.
- Conditions
- Healthy Volunteers, Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT04259801
- Testing
- NNC0480-0389, Semaglutide
- Where
- Netherlands
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment
This trial is conducted in Europe. The aim of this clinical trial is to compare the change in trunk fat mass, assessed by Double Energy X-ray Absorptiometry (DEXA) after 26 weeks of treatment with insulin detemir or insulin NPH…
- Trial name
- NCT00795600
- Testing
- insulin detemir, insulin NPH
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Vitamin D, K2 Plus Empagliflozin Combination in Type Two Diabetes Mellitus
The main purpose of the VETA trial is to verify the potential beneficial effects of the combination of micronutrients namely Vitamin D3 and K2 in combination with oral antihyperglycemic Empagliflozin in Diabetes Mellitus
- Trial name
- VETA (NCT05417880)
- Testing
- Oral Hypoglycemic Agents,Oral, Voreta, Voreta plus SunnyD PRO
- Where
- Pakistan
- Volunteers
- 340 people
- Sponsor
- Scotmann Pharmaceuticals
Healthy
Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy Volunteers
The purpose of this study is to determine whether treatment with a fixed dose combination dapagliflozin/metformin tablet is affected by food.
- Trial name
- NCT01156246
- Testing
- Dapagliflozin/Metformin
- Where
- Sweden
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)
This study compares insulin icodec (a new insulin) to insulin degludec (an insulin already available on the market) in people with type 1 diabetes.
- Trial name
- ONWARDS 6 (NCT04848480)
- Testing
- insulin icodec, insulin degludec, insulin aspart
- Where
- 130 sites in United States, Austria and 10 more
- Volunteers
- 582 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 Diabetes
GSK189075 is intended for use as a single treatment or in combination with other treatments for tye 2 diabetes mellitus (T2DM). Metformin is widely used in Europe and the USA for the treatment of T2DM.
- Trial name
- NCT00376038
- Testing
- GSK189075 oral tablets, metformin tablets
- Where
- Mexico
- Volunteers
- 13 people
- Sponsor
- GlaxoSmithKline